Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells

Cancer Research

Volumn 72, Issue 17, 2012, Pages 4405-4416

  Du, Xiaoli ^a   Qian, Xiaolan ^a   Papageorge, Alex ^a   Schetter, Aaron J ^a   Vass, William C ^a   Liu, Xi ^a   Braverman, Richard ^a   Robles, Ana I ^a   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; DELETED IN LIVER CANCXER 1 PROTEIN; MESSENGER RNA; RHO KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CAV 1 GENE; CONTROLLED STUDY; DELETED IN LIVER CANCXER 1 GENE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE INTERACTION; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CAVEOLIN 1; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTPASE-ACTIVATING PROTEINS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; PROGNOSIS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TRANSPORT; TUMOR SUPPRESSOR PROTEINS;

EID: 84865798462     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0777     Document Type: Article

References (53)

1. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196-9.
2. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 2008;40:843-7.
3. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, et al. DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007;11:1185-207.
4. Zhong D, Zhang J, Yang S, Soh UJ, Buschdorf JP, Zhou YT, et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci 2009;122:414-24.
5. Kim TY, Vigil D, Der CJ, Juliano RL. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 2009;28:77-83.
6. Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005;65:8861-8.
7. Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye MA. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res 2008;68:8743-51.
8. Alpy F, Tomasetto C. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J Cell Sci 2005;118:2791-801.
9. Clark BJ. The mammalian START domain protein family in lipid transport in health and disease. J Endocrinol 2012;212:257-75.
10. Liao YC, Si L, deVere White RW, Lo SH. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 2007;176:43-9.
11. Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A 2007;104:9012-7.
12. Chan LK, Ko FC, Ng IO, Yam JW. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One 2009;4:e5572.
13. Yam JW, Ko FC, Chan CY, Jin DY, Ng IO. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 2006;66:8367-72.
14. Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci U S A 2011;108:17129-34.
15. Yang X, Popescu NC, Zimonjic DB. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res 2011;71:2916-25.
16. Yang XY, Guan M, Vigil D, Der CJ, Lowy DR, Popescu NC. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 2009;28:1401-9.
17. Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 1989;264:20163-6.
18. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008;27:715-35.
19. Qian X, Li G, Vass WC, Papageorge A, Walker RC, Asnaghi L, et al. The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell 2009;16:246-58.
20. Anborgh PH, Qian X, Papageorge AG, Vass WC, DeClue JE, Lowy DR. Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf. Mol Cell Biol 1999;19:4611-22.
21. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004;78:751-7.
22. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, Litle VR, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008;36:6535-47.
23. Gene Expression Omnibus. [Cited 2012 Jul 1] Available from: http://www.ncbi.nlm.nih.gov/geo/.
24. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
25. caArray Array Data Management System. [Cited 2012 Jul 1]. Available from: https://array.nci.nih.gov/caarray/project/details.action?project.experiment. publicIdentifier=jacob-00182.
26. Yamaga M, Sekimata M, Fujii M, Kawai K, Kamata H, Hirata H, et al. A PLCdelta1-binding protein, p122/RhoGAP, is localized in caveolin-enriched membrane domains and regulates caveolin internalization. Genes Cells 2004;9:25-37.
27. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008;36:6535-47.
28. Ellenbroek SI, Collard JG. Rho GTPases: functions and association with cancer. Clin Exp Metastasis 2007;24:657-72.
29. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796:91-8.
30. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010;10:842-57.
31. Garcia-Mata R, Boulter E, Burridge K. The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol 2011;12: 493-504.
32. Durkin ME, Ullmannova V, Guan M, Popescu NC. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is down-regulated in cancer and inhibits tumor cell growth. Oncogene 2007;26:4580-9.
33. Liao YC, Shih YP, Lo SH. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res 2008;68:7718-22.
34. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001;58:811-4.
35. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am J Clin Pathol 2003;120:93-100.
36. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 2001;7:3519-25.
37. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002;94:929-33.
38. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-80.
39. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003;97:1225-33.
40. Tse EY, Ko FC, Tung EK, et al. Caveolin-1 overexpression is associated with hepatocellular carcinoma tumorigenesis and metastasis. J Pathol 2012;226:645-53.
41. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest 2001;108:1553-61.
42. Li M, Chen H, Diao L, Zhang Y, Xia C, Yang F. Caveolin-1 and VEGF-C promote lymph node metastasis in the absence of intratumoral lymphangiogenesis in non-small cell lung cancer. Tumori 2010;96:734-43.
43. Kopantzev EP, Monastyrskaya GS, Vinogradova TV, Zinovyeva MV, Kostina MB, Filyukova OB, et al. Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. Lung Cancer 2008;62:23-34.
44. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003;42:195-202.
45. Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, et al. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett 2004;214:121-8.
46. Shatz M, Lustig G, Reich R, Liscovitch M. Caveolin-1 mutants P132L and Y14F are dominant negative regulators of invasion, migration and aggregation in H1299 lung cancer cells. Exp Cell Res 2010;316:1748-62.
47. Lavigne P, Najmanivich R, Lehoux JG. Mammalian StAR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. Subcell Biochem 2010;51:425-37.
48. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003;426:803-9.
49. Olayioye MA, Vehring S, Müller P, Herrmann A, Schiller J, Thiele C, et al. StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. J Biol Chem 2005;280:27436-42.
50. Kanno K, Wu MK, Agate DS, Fanelli BJ, Wagle N, Scapa EF, et al. Interacting proteins dictate function of the minimal START domain phosphatidylcholine transfer protein/StarD2. J Biol Chem 2007;282: 30728-36.
51. Horibata Y, Sugimoto H. StarD7 mediates the intracellular trafficking of phosphatidylcholine to mitochondria. J Biol Chem 2010;285:7358-65.
52. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 2010;8:86.
53. Tripathi SC, Kaur J, Matta A, Gao X, Sun B, Chauhan SS, et al. Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma. Mod Pathol 2012;25:14-25.